<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199846</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-983</org_study_id>
    <nct_id>NCT03199846</nct_id>
  </id_info>
  <brief_title>Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States</brief_title>
  <official_title>Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect real-world data from advanced melanoma diagnosis through most recent
      visit and data sourced from patient medical records following a 2-part study design
      consisting of a random sample (Part 1) and an oversample (Part 2).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 25, 2016</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of treatment patterns for advanced melanoma patients</measure>
    <time_frame>Aproximately 6 months</time_frame>
    <description>Distribution of treatment patterns for advanced melanoma patients including, treatment regimen selection and rationale, as well as time to initiation of therapy and type of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of prescribing patterns</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Distribution of prescribing patterns by type of practice setting and melanoma patient volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Patient Age at index date</measure>
    <time_frame>at baseline</time_frame>
    <description>Patient Age at index date will be determined from Medical Records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Patient's Sex at Index Date</measure>
    <time_frame>At Baseline</time_frame>
    <description>Patient's sex will be determined from Medical Records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Comorbidities at index date</measure>
    <time_frame>At Baseline</time_frame>
    <description>Comorbidities will be determined using the Charlson Comorbidity Index (CCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Healthcare Coverage type</measure>
    <time_frame>At Baseline</time_frame>
    <description>Healthcare Coverage type will be determined using Medical Records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Diagnosis Date</measure>
    <time_frame>At Baseline</time_frame>
    <description>Melanoma Diagnosis Date will be determined using medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Advanced Diagnosis Date</measure>
    <time_frame>At Baseline</time_frame>
    <description>Date of advanced/ metastatic melanoma diagnosis will be determined using medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Age at Onset</measure>
    <time_frame>At Baseline</time_frame>
    <description>Diagnosis date-Date of Birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Disease stage at time of diagnosis</measure>
    <time_frame>At Baseline</time_frame>
    <description>Disease stage at time of diagnosis will be determined using medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Disease stage at subsequent visits</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Disease stage at subsequent visits will be determined using medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of ECOG status at Baseline</measure>
    <time_frame>At Baseline</time_frame>
    <description>Eastern Cooperative Oncology Group (ECOG) status at Baseline will be determined using medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of ECOG status at Last Visit</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Eastern Cooperative Oncology Group (ECOG) status at Last Visit will be determined using medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Biomarker status at baseline</measure>
    <time_frame>at baseline</time_frame>
    <description>Biomarker status will be determined using Medical Records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of treatment-related adverse events</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>treatment-related adverse events will be determined using medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Overall Survival (OS) from Advanced Diagnosis</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Date of death minus advanced/metastatic diagnosis date, censoring for LTF or end of observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Progression-Free Survival (PFS) at Advanced Diagnosis</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Date of progression (increase in tumor size or increase in cancer stage)/start of next line of therapy minus advanced/metastatic diagnosis date, censoring for LTF or end of observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Overall Response Rate (ORR)</measure>
    <time_frame>Approximately 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Overall Survival (OS) from Index Date</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Date of death minus index treatment start date, censoring for LTF or end of observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Progression-Free Survival (PFS) at Index Date</measure>
    <time_frame>Approximately 16 months</time_frame>
    <description>Date of progression (increase in tumor size or increase in cancer stage)/start of next line of therapy minus index treatment start date, censoring for LTF or end of observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of melanoma related HCRU</measure>
    <time_frame>Approximately 16 months</time_frame>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">650</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>advanced melanoma patients</arm_group_label>
    <description>Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipi monotherapy</arm_group_label>
    <description>Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ipi + nivo combination therapy</arm_group_label>
    <description>Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + trametinib combination therapy</arm_group_label>
    <description>Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembro monotherapy</arm_group_label>
    <description>Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo monotherapy</arm_group_label>
    <description>Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>advanced melanoma patients</arm_group_label>
    <arm_group_label>Ipi monotherapy</arm_group_label>
    <arm_group_label>Ipi + nivo combination therapy</arm_group_label>
    <arm_group_label>Dabrafenib + trametinib combination therapy</arm_group_label>
    <arm_group_label>Pembro monotherapy</arm_group_label>
    <arm_group_label>Nivo monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients initiating a new line of therapy for unresectable stage III and/or metastatic
        (stage IV) melanoma during the index period between 01-Jan-2015 and 31-May-2016.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years or older

          -  Diagnosis of unresectable stage III and/or metastatic (stage IV) melanoma before
             01-Nov-2015

          -  Initiating a new line of therapy during the index period between 01-Jan-2015 and
             31-May-2016, irrespective of advanced melanoma diagnosis date

          -  Medical history available for medical chart abstraction from date of diagnosis through
             most recent or current therapy (defined as end of data collection period)

        Exclusion Criteria:

          -  Physicians unwilling or unable to follow study instructions

          -  Patients who were previously enrolled in a cancer treatment-related clinical trial
             since the diagnosis of unresectable stage III and/or metastatic (stage IV) melanoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

